---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-039773"
form_type: "8-K"
ticker: "RVMD"
cik: "0001628171"
company_name: "Revolution Medicines, Inc."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T02:07:08.700628+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Revolution Medicines Q2 net loss $98.3M; clinical updates for RMC-6236 and RMC-6291

## Summary
- Net loss of $98.3M vs $61.2M YoY; revenue from Sanofi collaboration $3.8M, down from $9.1M.
- Cash, equivalents and securities $909.5M at June 30, 2023, up from $644.9M at Dec 31, 2022.
- FY 2023 GAAP net loss guidance $360M–$400M; cash expected to fund operations into 2025.
- Planning pivotal single-agent trials for RMC-6236; combination trial with RMC-6291 starting in early 2024.
- Clinical data for RMC-6236 and RMC-6291 to be presented at ESMO and Triple Meeting in October 2023.

## SEC filing metadata
- accession: 0000950170-23-039773
- form_type: 8-K
- ticker: RVMD
- cik: 0001628171
- company_name: Revolution Medicines, Inc.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628171/000095017023039773/0000950170-23-039773-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628171/000095017023039773/rvmd-20230808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-039773
- JSON: https://secwatch.observer/filing/0000950170-23-039773.json
- Plain text: https://secwatch.observer/filing/0000950170-23-039773.txt

## Key facts
- Earnings Releases
  Revolution Medicines, Inc. reported financial results for the quarter ended June 30, 2023.
  - Period: the quarter ended June 30, 2023
  - Result: reported results
  source text: On August 8, 2023, Revolution Medicines, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1628171/000095017023039773/0000950170-23-039773-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.